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Abstract
Background and purpose: Stroke is a preventable disease
and acute ischaemic stroke can be effectively treated. Spe-
cific pharmacotherapy is recommended in either prevention
or acute ischemic stroke treatment. We aimed to evaluate the
use and the early and late outcomes impact of drugs admin-
istered before and in acute ischaemic stroke in a real world
practice.
Material and methods: Ischaemic stroke patients hospital-
ized between 1st March 2007 and 29th February 2008 and
reported in Polish Hospital Stroke Registry were analysed.
Fully anonymous data were collected with standardized, web-
based questionnaire with authorized access. Multivariate
regression models were used to adjust for case-mix and eval-
uate the impact of drugs used prior to or in acute ischaemic
stroke on outcomes. The early outcomes were defined as in-
hospital mortality or poor outcome (death or dependency –
modified Rankin Scale ≥ 3) at hospital discharge, while late
outcomes covered one-year survival. 
Pharmacotherapy prior to and in acute ischaemic stroke. 
The use of pharmacotherapy and drugs-associated outcomes in real-world practice
– findings from the Polish Hospital Stroke Registry
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St reszc zen ie  
Wstêp i cel pracy: Udarowi mózgu mo¿na skutecznie zapo-
biegaæ. Dostêpne s¹ efektywne metody leczenia ostrego uda-
ru niedokrwiennego. Zarówno w profilaktyce, jak i leczeniu
ostrego udaru niedokrwiennego zalecana jest specyficzna far-
makoterapia. Celem badania by³a ocena farmakoterapii sto-
sowanej przed zachorowaniem oraz w ostrej fazie udaru nie-
dokrwiennego mózgu, w warunkach codziennej praktyki
klinicznej. 
Materia³ i metody: Analizie poddano grupê chorych hospi-
talizowanych z powodu udaru niedokrwiennego mózgu od
1.03.2007 r. do 29.02.2008 r., zg³oszonych do Szpitalnego
Rejestru Udarów Mózgu w Polsce. W pe³ni anonimowe dane
gromadzono z wykorzystaniem strukturyzowanego kwestio-
nariusza internetowego z autoryzowanym dostêpem. Do oce-
ny wp³ywu leków (stosowanych przed zachorowaniem oraz
w ostrej fazie udaru niedokrwiennego) na rokowanie wyko-
rzystano wieloczynnikow¹ analizê regresji z uwzglêdnieniem
wp³ywu innych czynników rokowniczych. Wczesne wyniki
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Introduction
Stroke, as a one of the leading causes of mortality
and disability, is also very preventable and curable dis-
ease. Oxford Vascular Study showed 40% decrease in
the age-specific incidence of major stroke in Oxford-
shire from 1981 to 2004 [1].Ten risk factors (i.e. histo-
ry of hypertension, current smoking, obesity measured
with waist-to-hip ratio, diet, physical activity, diabetes
mellitus, alcohol intake, psychosocial stress and depres-
sion, cardiac causes and dyslipidaemias) are associated
with 90% of the risk of stroke [2]. Some of these risk
factors can be addressed with specific and effective drug
treatment. Therefore, apart from non-drug prevention
methods, pharmacotherapy plays an important role in
prevention of first-ever stroke as well as secondary cere-
brovascular accident. Current guidelines in the prima-
ry prevention of stroke recommend targeting some of
the modifiable risk factors with a specific drug. Sec-
ondary prevention follows the primary management,
although intensification of treatment is well recognized
as some modifications. Current and previous Polish
guidelines issued in 2003 and 2008 recommended in
secondary prevention of stroke: antiplatelets (mainly
aspirin and ticlopidine as clopidogrel was not reimbursed
until 2007 and combined preparation of aspirin and
dipiridamol is not available in Poland so far), anticoag-
ulants in atrial fibrillation (AF) patients, statins and
blood pressure lowering agents (the last two should be
considered for all ischaemic stroke patients) [3,4]. Sec-
ondary prevention of stroke should be established before
hospital discharge. More evidence is reported on ben-
efits produced by effective control of risk factor that
reduces not only incidence but also stroke severity and
improves outcome.
Stroke is also a curable disease. So far, acute ischae -
mic stroke specific drug treatment proved effective in
randomized controlled trials is aspirin and thrombolysis.
Aspirin is an immediate treatment after an ischaemic
stroke to reduce the likelihood of having another stroke.
Patients allocated to recombinant tissue plasminogen acti-
vator (rt-PA) up to 6 hours after stroke, are more likely
to be alive with less disability. Acute stroke complications
also need specific pharmacotherapy including antihy-
pertensives in very high blood pressure, antibiotics in
infections and antipyretics in fever, low molecular weight
heparins in prevention of deep vein thrombosis or insulin
in severe hyperglycaemia.
leczenia zdefiniowano jako œmiertelnoœæ wewn¹trzszpitaln¹
i niekorzystny efekt terapeutyczny (punktacja ≥ 3 w zmody-
fikowanej skali Rankina) przy wypisie ze szpitala, natomiast
odleg³e wyniki leczenia jako ca³kowit¹ œmiertelnoœæ w ci¹gu
pierwszego roku od udaru.
Wyniki: Analizie poddano dane 26 153 osób hospitalizowa-
nych z powodu udaru niedokrwiennego (œredni wiek: 71,8
roku; kobiety: 51,6%). Wykazano niewystarczaj¹ce profilak-
tyczne stosowanie leków hipotensyjnych, przeciwzakrzepo-
wych u chorych z migotaniem przedsionków, leków prze-
ciwp³ytkowych i statyn. W modelach wieloczynnikowych
odnotowano spodziewane korzystne efekty farmakoterapii.
Wykazano dodatkowo, ¿e leki hipotensyjne i kwas acetylosa-
licylowy stosowane przed zachorowaniem oraz leki przeciw-
zakrzepowe i statyny w trakcie hospitalizacji s¹ zwi¹zane
z korzystnymi wynikami terapeutycznymi.
Wnioski: Farmakologiczna profilaktyka udaru mózgu i lecze-
nie ostrego udaru mózgu wymagaj¹ dalszego monitorowania
i poprawy. Korzyœci z zastosowania statyn w leczeniu ostrego
udaru mózgu powinny byæ potwierdzone w badaniach kli-
nicznych z randomizacj¹. 
S³owa kluczowe: udar niedokrwienny, farmakoterapia, leki
przeciwzakrzepowe, kwas acetylosalicylowy, leki hipotensyj-
ne, statyny. 
Results: A total number of 26 153 ischaemic stroke patients
(mean age: 71.8 years; females: 51.6%) was reported. The ana -
lysis of pharmacotherapy showed that preventive use of hypo -
tensive agents, anticoagulants in atrial fibrillation, antiplatelets
and statins is inadequate. Regression models confirmed some
expected drug benefits and additionally revealed that antihy-
pertensive drugs or aspirin used prior to stroke and oral anti-
coagulants or statins used in hospital were associated with
better stroke outcome.
Conclusions: The prevention of ischaemic stroke needs to be
monitored and improved. Evidence-based treatment of acute
ischaemic stroke requires further promotion. The benefits of
acute ischaemic stroke treatment with statins require to be
confirmed in randomized controlled settings.
Key words: ischaemic stroke, pharmacotherapy, aspirin, oral
anticoagulants, antihypertensives, statins.
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We aimed to evaluate the use and the early and late
outcomes impact of drugs administered before and in acute
ischaemic stroke patients reported in the Polish Hospital
Stroke Registry and hospitalized in 2007 and 2008.
Material and methods
Data on hospitalized stroke patients reported with-
in third edition of Polish Hospital Stroke Registry cov-
ering time-frame from 1st March 2007 to 29th Febru-
ary 2008 were analysed. All neurological centres in
Poland were invited to participate and voluntarily report
fully anonymous stroke patients data. Stroke was defined
according to WHO definition as a neurological deficit
of cerebrovascular cause that persists beyond 24 hours
or is interrupted by death within 24 hours.
Data were collected with standardized web-based
questionnaire, specially designed to eliminate misre-
porting and based on Swedish Stroke Registry and
WHO STEPwise approach to Surveillance. The access to
registry was dedicated to each participating centre and
protected from unauthorised use. Data were reported
fully anonymously and, additionally, analysed with blind-
ed information on patients’ allocation to particular stroke
centre. To ensure the quality of reported data, random-
ly selected centres were audited. The following infor-
mation was reported for all patients: demographics (age,
gender), cardiovascular risk factors, mRS prior to stroke,
time of symptom onset (if unknown, the time patient was
last seen symptomless), clinical status at admission (lev-
el of consciousness), hospital management, stroke out-
comes (modified Rankin Scale [mRS] at discharge) and
drugs used before stroke, during hospital stay and pre-
scribed on discharge. The manual including all impor-
tant terms and definitions and easily accessible on the
official website of the Registry was provided. The histo-
ry of cerebrovascular events was defined as documented
hospitalisation due to confirmed stroke or TIA. Hyper-
tension was reported for patients diagnosed before or
during index hospitalization (by repeated blood pressure
measurements after acute phase, i.e. first seven days);
threshold values for hypertension were based on JNC
VII report (systolic blood pressure > 140 mm Hg or 
> 130 mm Hg for diabetic or chronic renal failure pa -
tients; diastolic blood pressure > 90 mm Hg or > 80 mm
Hg for diabetic or chronic renal failure) [5]. Atrial fib-
rillation encompassed paroxysmal, persistent and per-
manent arrhythmias. Ischaemic heart disease could have
been only reported for patients objectively diagnosed with
either interventional or non-inter ventional methods. 
The history of myocardial infarction was defined as acute
coronary syndrome treated in hospital 30 days before
stroke onset. Finally, dyslipidaemias could have been
reported only if laboratory tests conducted 3 months pre-
ceding stroke onset or during first 24 hours were avail-
able for the following: total cholesterol (> 200 mg%) or
LDL cholesterol (> 100 mg%) or triglycerides (> 150
mg%) or HDL cholesterol (< 40 mg% for males and
50 mg% for females). The fol lowing drug groups were
distinguished: aspirin, other antiplatelets, rt-PA, blood
pressure lowering agents, oral anticoagulants, heparins,
insulins, oral antidiabetic drugs, vasoactive (i.e. nicer-
goline, vinpocetine) and neuroprotective agents (i.e.
piracetam), statins, antibiotics. In the third edition of Pol-
ish Hospital Stroke Registry, unique Polish Resident
Identification Number (PESEL) was used to track an -
nual survival of stroke patients based on data collected
by Department of National Central Evidences run by
Ministry of Internal Affairs and Ad ministration.
Statistical analysis
Data were analysed separately for ischaemic stroke
following ICD-10 classification (I63). Calculations and
estimations were conducted for the whole ischaemic stroke
patients population and appropriate subgroups identified,
i.e. target population for studied drugs. Data were pre-
sented as numbers and corresponding percentages.
Multivariate regression models were used to adjust
for case-mix and evaluate the impact of drugs used pri-
or to or in acute ischaemic stroke on outcomes. The ear-
ly outcomes were defined as in-hospital mortality or poor
outcome (death or dependency – mRS ≥ 3) at hospital
discharge. The late outcomes covered one-year follow-
up and the number of days from stroke onset to death
for fatal cases. Logistic regression models and Cox pro-
portional hazard model were applied for early and late
outcomes, respectively. Dedicated models controlled for
distribution of age, sex, cardiovascular risk factors, dis-
ability assessed with mRS prior to stroke, consciousness
at admission and treatment centres.
Results
A total number of 123 stroke centres reported data
on 26 153 ischaemic stroke patients in the third edition
of Polish Hospital Stroke Registry, including 94 centres
which registered at least 100 patients.
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Mean age of patients was 71.8 years (95% confidence
interval [CI]: 71.7-71.9). For patients with first-ever
stroke, mean age was 71.6 (95% CI: 71.4-71.8). Females
represented 51.6% of the registered population. Table 1
shows baseline characteristics, including cardiovascular
risk factors. Hypertension was most prevalent stroke risk
factor, followed by ischaemic heart disease, dyslipidae -
mias, atrial fibrillation and diabetes. At least third patient
was admitted within 4.5 hours from stroke onset.
The detailed analysis of pharmacotherapy used in
patients prior to and in acute ischaemic stroke patients
for general patients population and subgroups is shown
in the Table 2.
Regression models after adjusting for case-mix con-
firmed some expected drug benefits, i.e. aspirin used at
hospital was associated with better early and late prog-
nosis (in-hospital death: OR = 0.54 [95% CI: 0.49-
0.61]; poor outcome at discharge: OR = 0.85 [95% CI:
0.78-0.92], one year mortality: OR = 0.78 [95% CI:
0.74-0.83]). Antihypertensive drugs used prior to stroke
were associated with lower odds of early and late mor-
tality. Both oral anticoagulants and statins implemented
during hospital stay were related to lower in-hospital
N %
History of stroke 5847 22.4
Hypertension 19 010 72.7
Atrial fibrillation 6168 23.6
Ischaemic heart disease 8305 31.8
History of myocardial infarction 2627 10.04
Diabetes 6141 23.5
Smoking 3489 13.3
Alcohol abuse 1389 5.3
Dyslipidaemias 6722 25.7
Modified Rankin scale score prior to stroke:
0 13 678 55.1
1 3866 15.6
2 2843 11.5
3 1749 7.0
4 1583 6.4
5 1128 4.5
Time from onset to admission 8398 32.1
< 4.5 hours (including missing data
or unknown time of onset)
Consciousness disturbances:
Alert 19 907 76.2
Drowsy 4095 15.7
Stupor 1297 5.0
Coma 819 3.1
Table 1. Baseline characteristics of ischaemic stroke patients reported 
in the third edition of Polish Hospital Stroke Registry
Drugs used prior to stroke N %
Blood pressure lowering agents 14 594 75.8
in hypertensive patients
Blood pressure lowering agents 4184 71.6
in patient with history of stroke
Antiplatelets in patients with history 3474 59.4
of stroke
Antiplatelets in patients with history 4704 52.3
of MI or IHD
Oral anticoagulants in patients with AF 668 10.83
Statins 4020 15.37
Statins in patients with history of stroke 1451 24.8
Statins in patients with history of MI 2290 25.5
or IHD
Statins in patients with dyslipidaemias 2085 31.0
Vasoactive agents 1470 5.6
Neuroprotective agents 1895 7.3
Antibiotics 244 0.9
Drugs used during hospital stay N %
rtPA– thrombolysis 296 1.1
Blood pressure lowering agents 20 008 76.5
Blood pressure lowering agents  17 097 89.9
in hypertensive patients
Aspirin 21 484 82.1
Other antiplatelets 2159 8.26
Oral anticoagulants in AF patients 1150 18.6
Heparins 8269 31.6
Statins 11 848 45.3
Insulin 3087 50.3
Antibiotics 7469 28.6
Vasoactive agents 6425 24.6
Neuroprotective agents 14 281 54.6
Table 2. Pharmacotherapy prior to stroke and used during hospital stay
MI – myocardial infarction, IHD – ischaemic heart disease, AF – atrial fibrillation, 
rt-PA – recombinant tissue plasminogen activator
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mortality and risk of poor outcome at discharge. The lat-
ter used prior to stroke, as well as aspirin before stroke
onset, were associated with better functional outcome at
discharge. Drugs used prior to or in acute ischaemic
stroke and found in multivariate regression models sta-
tistically significantly associated with early and late out-
comes are presented in Table 3.
Discussion
Drug utilisation before cerebrovascular accident and
in acute ischaemic stroke is important in monitoring of
the current medical practice. It can also show the ben-
efit of pharmacotherapy in real world settings. Data from
the Polish Hospital Stroke Registry provide a unique
opportunity to both – the evaluation of the current prac-
tice and providing evidences on possible drug related
benefit based on everyday clinical practice data.
The pharmacotherapy practice prior to and in acute
ischaemic stroke
Antihypertensive drugs were used prior to stroke on
average by three out of four patients with hypertension
in the Polish Hospital Stroke Registry. Compared to
findings from other national registries it is less than in
England, Wales and North Ireland, where almost 82%
of hypertensive patients were treated with blood pressure
lowering agents before stroke onset, but substantially
more than in Sweden (55% of hypertensive males and
59% hypertensive females) [6,7]. We lack data on effec-
tiveness of blood pressure control with antihypertensive
prior to ischaemic stroke in the Polish Hospital Stroke
Registry. Almost 90% of hypertensive patients were treat-
ed with blood pressure lowering compounds during hos-
pitalization. As blood pressure tends to fluctuate in acute
stroke, the assessment of antihypertensive agents is lim-
ited. However, only three quarters of total ischaemic
stroke population were treated with blood pressure low-
ering drugs while guidelines clearly state that treatment
must be considered in every, including normotensive,
stroke patient. As the secondary stroke prevention should
be established during hospital stay and hardly ever
hypotensive treatment needs late (after discharge) start,
thus one can argue there is still room to improve sec-
ondary prevention with blood pressure lowering agents.
Antiplatelets before stroke onset were used only by
half of patients with history of myocardial infarction or
Drugs associated with in-hospital mortality: p-value OR 95% CI
Antihypertensives prior to stroke 0.009 0.859 0.766-0.963
Antihypertensives in hospital 0.005 0.836 0.750-0.933
Aspirin in hospital < 0.001 0.544 0.489-0.607
Oral anticoagulants in hospital 0.027 0.764 0.600-0.966
Statins in hospital < 0.001 0.518 0.464-0.577
Antibiotics in hospital < 0.001 3.710 3.372-4.084
Drugs associated with functional outcome at discharge:
Aspirin prior to stroke 0.004 0.898 0.833-0.967
Statins prior to stroke < 0.001 0.822 0.746-0.906
Aspirin in hospital < 0.001 0.849 0.780-0.923
Oral anticoagulants in hospital < 0.001 0.540 0.457-0.638
Statins in hospital < 0.001 0.932 0.873-0.996
Antibiotics in hospital < 0.001 2.681 2.152-3.352
Drugs associated with one year survival:
Antihypertensives prior to stroke 0.001 0.904 0.854-0.957
Aspirin in hospital < 0.001 0.782 0.740-0.826
Table 3. The statistically significant findings of multivariate regression models on the drugs associated with early and late ischaemic stroke outcome
OR – odds ratio, CI – confidence interval
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ischaemic heart disease and slightly more often in pa -
tients with secondary stroke. Aspirin, especially used
within 24 hours from stroke onset, if thrombolysis is not
implemented, is established stroke care quality indica-
tor as it is the only one antiplatelet of evidence-based
benefit confirmed also in our study results or other Pol-
ish trials [8-11].The use of aspirin in acute ischaemic
stroke in Poland is very similar to other countries [12,
13]. Not only aspirin use, but the timing of its applica-
tion (first 48 hours) is important and that needs further
assessment in Polish clinical practice. 
Low use of anticoagulants in AF patients prior to
stroke needs special consideration as AF is important
risk factor of stroke and anticoagulants are very effec-
tive in preventing it. Hardly every tenth ischaemic stroke
patient with AF received anticoagulants prior to stroke
and that is very similar to findings from Swedish Stroke
Registry, Danish Stroke Registry for secondary stroke
patients and international European study of first-ever
stroke [14-16]. Only in SAFE II study, the correspond -
ing anticoagulant use rate was 22.2% but it was report-
ed for patients with diagnosed AF and confirmed in
ECG within 24 months prior to stroke [17]. Anticoag-
ulation in AF stroke patients is also established stroke
care quality indicator. In acute ischaemic stroke, use of
oral anticoagulants should be started within first 2 weeks
– the later the more severe stroke is. It should be stressed
that less than 19% of ischaemic stroke patients with AF
had treatment with oral anticoagulants initiated during
hospital stay and only 21% were prescribed these drugs
at discharge (data not presented). Substantial inter-coun-
tries variability in oral anticoagulants ordered at hospi-
tal discharge of AF stroke patients is well documented.
In Sweden one-third of patients (even 46% of patients
discharged home) is offered oral anticoagulants at hos-
pital discharge. In cited SAFE II study, the corre-
sponding value was 58.1% (range: 40.8% for Italy to
67.5% for France), but authors concluded that antici-
pated percentage of patients eligible (with no con-
traindications) for long-term oral anticoagulation can
reach even 80%. Therefore further monitoring and
improvement in that aspect of preventive stroke phar-
macotherapy is more than justified. The availability of
new oral anticoagulants could probably contribute to
better control of stroke risk in AF patients.
Thrombolysis, the only beneficial drug therapy in
acute ischaemic stroke apart from aspirin, was used only
for 1.1% of studied population but since 2005 dedicat-
ed registry to rt-PA in stroke was operating (Tromboliza
w Udarze Mózgu – TUM) the Polish Hospital Stroke
Registry was probably affected by underreporting of that
treatment as specific data on its use was collected else-
where.
Statins were used only for one fourth of patients with
history of stroke or myocardial infarction and ischaemic
heart disease. One can expect that availability of statins
generics contribute currently to their higher utilization
in clinical practice. Nevertheless, use of statins prior to
stroke was more driven by dyslipidaemias than cardio-
vascular diseases and did not reflect clinical guidelines.
Statins were used only in 45% of patients during hospi-
tal stay. Although statins are not recommended in acute
ischaemic stroke treatment, they should be considered
in secondary prevention for every patient, thus these
drugs seem to be underused in the Polish Hospital
Stroke Registry.
Almost one third of acute ischaemic stroke patients
were treated with heparins as low molecular weight
heparins were shown to be effective in prevention of
deep venous thrombosis in bed-driven patients [18,19].
As data on type of heparin used were not available, the
more in depth analysis was not possible, but it should
be noted that high doses of heparins were not shown to
be beneficial in stroke patients and unfractionated he -
parins are less popular in Poland as well as reported very
rarely in Swedish Stroke Registry [20,21].
Antibiotics use reflects the risk of infectious com-
plications and indirectly indicates the quality of acute
stroke care. The prophylactic treatment with antibiotics
is neither effective nor recommended [22]. Almost one
third of ischaemic stroke patients in the Polish Hospi-
tal Stroke Registry was treated with antibiotics in hos-
pital and that is in accordance with systematic review of
87 studies involving 137 817 patients, which estimated
the overall pooled infection rate complicating acute
stroke at 30% and even 45% for intensive care unit stud-
ies [23].
Finally, the vasoactive (i.e. nicergoline, vinpocetine)
and neuroprotective compounds (i.e. piracetam) are still
popular in the management of acute ischaemic stroke.
These drugs have not been shown effective in random-
ized clinical trials. Although these drugs are less and
less common in following edition of the Polish Hospi-
tal Stroke Registry (data not presented; in first edition
of the Polish Hospital Stroke Registry the correspond-
ing rate was 33.1 and 79.9%, respectively), they are still
fairly popular. As a kind of negative indicator, the use of
vasoactive and neuroprotective agents can be used to
reflect the dissemination of evidence-based clinical prac-
tice. It should be stressed that these drugs were used
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rarely prior to stroke and much more often during hos-
pital stay, thus hospital management results in increased
use of these drugs and therefore should be further mon-
itored and improved.
The impact of drugs used before cerebrovascular
accident or in acute ischaemic stroke on patients
prognosis
The findings from the Polish Hospital Stroke Reg-
istry should be interpreted with caution as it is explorato-
ry analysis and can be only used to generate hypotheses
that need to be confirmed in randomized controlled set-
tings.
The early and long-term survival benefit of antihy-
pertensive agents used prior to stroke observed in our
study was also noted for drugs blocking renin-angio -
tensin-aldosterone system and confirmed by Grabska 
et al. in the analysis of stroke patients admitted to 2nd
Neurological Department of Institute of Psychiatry and
Neurology in Warsaw [24-26].
In our study, statins used prior to stroke were asso-
ciated with lower risk of poor outcome at discharge. The
benefit of these drugs used before stroke was confirmed
in systematic review of 13 clinical trials, especially for
patients with diabetes, elderly and concomitant hyper-
tension or other cardiovascular diseases as well as for
those with normal LDL cholesterol concentration [27].
In meta-analysis, Cordenier et al. also noted beneficial
impact of pre-treatment with statin on in-hospital mor-
tality, but did not observe improvement on 3 month
functional outcome [28].
Stimulating finding from our study, justifying future
clinical trials, concerns the early benefits (reduced in-
hospital mortality and improved functional outcome at
discharge) associated with statin use during hospital stay.
In Cochrane systematic review, 8 clinical trials on statin
use within first 2 weeks from TIA or stroke onset were
identified [29]. Authors concluded that data available
from randomized trials are still insufficient to establish
whether statins are safe and effective in cases of acute
ischaemic stroke and TIA and further randomized clin-
ical trials are needed.
The benefit of oral anticoagulants observed in our
study reflects rather the quality of stroke care (as spe-
cific data on the quality of stroke care were limited we
could not fully control for that confounder) then the real
advantage of these drugs used in acute stroke.
Our study has a number of limitations, some of them
were already mentioned. Main limitation is voluntarily
reported, not fully representative, sample of registered
patients and limited scope of collected data. Neverthe-
less it is so far the largest study on real world everyday
stroke care in Poland.
Conclusions 
1. The prevention of ischaemic stroke with blood pres-
sure lowering agents, anticoagulants in AF, anti -
platelets and statins is inadequate and needs to be
monitored and improved.
2. Evidence-based treatment of acute ischaemic stroke,
as reflected by more aspirin and thrombolysis and less
neuroprotective drugs use, requires further promo-
tion.
3. The benefits of acute ischaemic stroke treatment with
statins require confirmation in randomized controlled
settings.
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